Kishore Khot, MD
Psychiatry · Cape Girardeau, MONPI 1568573038
Payments from drug & device makers
Across 620 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Alkermes, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$896
- Teva Pharmaceuticals USA, Inc.$800
- Otsuka America Pharmaceutical, Inc.$780
- plus $2K from 13 others
What the payments were for
- Consulting fees$3,68029%
- Food & beverage$8,80870%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 28 | $4,120 |
| Alkermes, Inc. | 120 | $2,178 |
| AbbVie(2 entities) | 145 | $1,809 |
| Johnson & Johnson | 54 | $896 |
| Teva Pharmaceuticals USA, Inc. | 41 | $800 |
| Otsuka America Pharmaceutical, Inc. | 70 | $780 |
| Neurocrine Biosciences, Inc. | 25 | $454 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $342 |
| Sunovion Pharmaceuticals Inc. | 61 | $256 |
| Vanda Pharmaceuticals Inc. | 18 | $250 |
| Lundbeck LLC | 10 | $191 |
| Indivior Inc. | 7 | $128 |
| Axsome Therapeutics, Inc. | 7 | $117 |
| Merck | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Braeburn Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$401
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- CAPLYTA$122
- SPRAVATO$121
- ARISTADA INITIO$100
How this compares
$12,584 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 21 | $209,176 |
| Invega SustennaPaliperidone Palmitate | 59 | $191,009 |
| IngrezzaValbenazine Tosylate | 15 | $125,183 |
| RexultiBrexpiprazole | 80 | $116,399 |
| AristadaAripiprazole Lauroxil | 25 | $67,328 |
| VraylarCariprazine Hcl | 40 | $57,205 |
| Abilify MaintenaAripiprazole | 13 | $40,568 |
| Austedo XrDeutetrabenazine | 15 | $32,934 |
| TrintellixVortioxetine Hydrobromide | 53 | $32,324 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $21,312 |
| Paliperidone ErPaliperidone | 60 | $13,634 |
| Aripiprazole | 159 | $10,797 |
| BelsomraSuvorexant | 23 | $10,453 |
| Divalproex Sodium ErDivalproex Sodium | 163 | $9,491 |
| Chlorpromazine Hcl | 34 | $9,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $896 | $400,18580 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $780 | $156,96793 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $454 | $125,18315 claims |
| Alkermes, Inc.Aristada, Lybalvi | $2,178 | $88,63937 claims |
| AbbVieVraylar | $1,809 | $57,20540 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $800 | $32,93415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $69 | $32,32453 claims |
| MerckBelsomra | $91 | $10,45323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Cape Girardeau
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
- Vadim BaramSaint Louis$1.9M
- Gary LinkerFordland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.